Additional administration of epinephrine, often in the form of an autoinjector (Epi-pen), is required by people with such hypersensitivities.
H-antihistamines can be administered topically (through the skin, nose, or eyes) or systemically, based on the nature of the allergic condition.
They reported that out of 390 CU patients who were treated with antihistamines 44% responded well, 29% became asymptomatic, and 15% showed partial improvement.
Research into aspects of pharmacokinetics and efficacy and adverse effect profiles of bilastine in children under 12 years of age is needed as are dose-response assessments and studies planned rigorously with the aim of assessing quality of life effects.
Current guidelines for diagnosis and treatment of allergic rhinoconjunctivitis and urticaria recommend nonsedating antihistamines as first line treatment [1, 2].
Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil.
Once released, the histamine can react with local or widespread tissues through histamine receptors.